Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin

Journal of Perinatal Medicine

Volumn 42, Issue 5, 2014, Pages 591-601

  Meiri, Hamutal ^a   Sammar, Marei ^b   Herzog, Ayelet ^c   Grimpel, Yael Inna ^a   Fihaman, Galina ^a   Cohen, Aliza ^a   Kivity, Vered ^a   Sharabi Nov, Adi ^d   Gonen, Ron ^e  

^a TeleMarpe Ltd   (Israel)

^b ORT BRAUDE COLLEGE   (Israel)

^c HY LABORATORIES LTD   (Israel)

^d Rebecca Sieff Government Hospital   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Aspirin prevention; In vitro fertilization; Mean arterial pressure; Multiple of the medians; Placenta; Placental protein 13; Preeclampsia; Risk factors; Risk prediction; Serum biomarkers

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; PLACENTA PROTEIN; PLACENTAL PROTEIN 13; PRESCRIPTION DRUG; UNCLASSIFIED DRUG; GALECTIN; LGALS13 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK PATIENT; HIGH RISK PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MEDICATION COMPLIANCE; NULLIPARA; PATIENT COMPLIANCE; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; MIDDLE AGED; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; GALECTINS; HUMANS; MIDDLE AGED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84903960546     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2013-0298     Document Type: Article

References (36)

1. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:66-74.
2. Balogh A, Pozsgay J, Matko J, Dong Z, Kim CJ, Varkonyi T, et al. Placental protein 13 (PP13/galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. Am J Obstet Gynecol. 2011;205:156 e1-14.
3. Bar J. The treatment approach for hypertension in pregnancy. Israel. Society of Obstetrics Gynecology. 18. 03. 2009. http://www.obgyn.org.il/niarEmda-info.asp?info-id=56381.
4. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402-14.
5. Calhoun KC, Barnhart KT, Elovitz MA, Srinivas SK. Evaluating the Association between Assisted Conception and the Severity of Preeclampsia. ISRN Obstet Gynecol. 2011;2011:928592.
6. Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta. 2011;32:S4-16.
7. Cuckle HS. Screening for pre-eclampsia - lessons from aneuploidy screening. Placenta. 2011;32:S42-8.
8. Gebhardt S, Bruiners N, Hillermann R. A novel exonic variant (221delT) in the LGALS13 gene encoding placental protein 13 (PP13) is associated with preterm labour in a low risk population. J Reprod Immunol. 2009;82:166-73.
9. Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56:361-75.
10. Gizurarson S, Huppertz B, Osol G, Skarphedinsson JO, Mandala M, Meiri H. Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents. Fetal Diagn Ther. 2013;33:257-64.
11. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG. 2008;115:1465-72.
12. Grimpel YI, Kivity V, Cohen A, Meiri H, Sammar M, Gonen R, et al. Effects of calcium, magnesium, low-dose aspirin and low-molecular-weight heparin on the release of PP13 from placental explants. Placenta. 2011;32 Suppl: S55-64.
13. Gynecologists ACoOa. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Int J Gynaecol Obstet. 2002;77:67-75.
14. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51:970-5.
15. Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Hum Reprod Update. 2013;19:391-405.
16. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol. 2010;35:671-9.
17. Lindheimer MD, Taler SJ, Cunningham FG. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich). 2009;11:214-25.
18. Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol. 2011;23:440-719.
19. NICE. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. 2010.
20. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27:13-7.
21. Onwudiwe N, Yu CK, Poon LC, Spiliopoulos I, Nicolaides KH. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol. 2008;32:877-83.
22. Orendi K, Gauster M, Moser G, Meiri H, Huppertz B. Effects of vitamins C and E, acetylsalicylic acid and heparin on fusion, beta-hCG and PP13 expression in BeWo cells. Placenta. 2010;31:431-8.
23. Pijnenborg R, Vercruysse L, Hanssens M. Fetal-maternal conflict, trophoblast invasion, preeclampsia, and the red queen. Hypertens Pregnancy. 2008;27:183-96.
24. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol. 2010;35:662-70.
25. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-4.
26. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357:53-6.
27. Sammar M, Nisemblat S, Fleischfarb Z, Golan A, Sadan O, Meiri H, et al. Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta. 2011;32 Suppl: S30-6.
28. Shmueli A, Meiri H, Gonen R. Economic assessment of screening for pre-eclampsia. Prenat Diagn. 2012;32:29-38.
29. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-99.
30. Svirsky R, Meiri H, Herzog A, Kivity V, Cuckle H, Maymon R. First trimester maternal serum placental protein 13 levels in singleton vs. twin pregnancies with and without severe pre-eclampsia. J Perinat Med. 2013;41:561-6.
31. Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA. 2009;106:9731-6.
32. Than NG, Romero R, Meiri H, Erez O, Xu Y, Tarquini F, et al. PP13, maternal ABO blood groups and the risk assessment of pregnancy complications. PLoS One. 2011;6:e21564.
33. Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem. 2011;286:30911-25.
34. WHO. Make every mother and child count. Geneva, Switzerland: World Health Organization, 2005.
35. Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG. 2010;117:1384-9.
36. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32:171-8.